Indications of Alectinib

1. Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Alectinib is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test.

2. Treatment of Metastatic ALK-Positive NSCLC

Alectinib is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected  by an FDA-approved test.

from FDA,2024.04